PatchMD Introduces New GLP-1 Support Patches for Individuals on Weight Loss Medications
PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
WebMD21d
What Drugs Are Being Researched for Obesity?
Whether it eventually gets approved depends on the results of those studies. Mazdutide is both a GLP-1 agonist and a glucagon receptor agonist. It works in two ways to promote weight loss in ...
Malaysian Reserve1y
Innovent’s First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Mazdutide is the first GLP-1R/GCGR dual agonist to successfully complete Phase 3 trials in support of a NDA submission. As a new generation of weight-loss drugs activating both GLP-1 and glucagon ...